A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function

Trial Profile

A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Chronic heart failure; Myocardial infarction; Sickle cell anaemia; Stroke; Veno-occlusive disorders
  • Focus Pharmacokinetics
  • Sponsors Mast Therapeutics
  • Most Recent Events

    • 20 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.
    • 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top